Publication | Open Access

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

VaccinationEscalation TrialTumor ImmunologySquamous Cell CarcinomaMedicineImmunologyVaccine TrialTherapeutic VaccineHead And Neck CancerNeck OncologyImmunotherapyOncologyRadiation OncologyCancer-associated Virus